Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients

Nature Clinical Practice Nephrology

Volumn 2, Issue 6, 2006, Pages 326-336

  Monge, Matthieu ^a   Shahapuni, Irina ^a   Oprisiu, Roxana ^b   El Esper, Najeh ^a   Morinière, Philippe ^a   Massy, Ziad ^b   Choukroun, Gabriel ^a   Fournier, Albert ^a,b  

^a Department of Nephrology Internal Medicine ^*  (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

1 OH vitamin D derivatives; Calcimimetics; Chronic kidney disease; Hyperparathyroidism; Oral phosphate binders

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; ALUMINUM HYDROXIDE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANTHANUM CARBONATE; NICOTINAMIDE; NICOTINIC ACID; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIALYSATE; DIALYSATE LEVEL; DISEASE COURSE; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MEDICAL SOCIETY; NONHUMAN; PARATHYROID HORMONE RELEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UREMIA; VITAMIN D DEFICIENCY;

BONE AND BONES; BONE DISEASES; CALCIFICATION, PHYSIOLOGIC; CALCIUM; EVIDENCE-BASED MEDICINE; HEMODIALYSIS SOLUTIONS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES; RENAL DIALYSIS; VITAMIN D DEFICIENCY;

EID: 33745947727     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0189     Document Type: Review

References (71)

1. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2003) Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 13): S1-S201
2. Shahapuni I et al. (2005) How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 18: 226-238
3. Block GA et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218
4. Fournier A et al. (2001) Optimal range of plasma concentration of true 1-84 parathyroid hormone in patients on maintenance dialysis. J Clin Endocrinol Metab 86: 1840-1842
5. Fournier AE et al. (1971) Etiology of hyperparathyroidism and bone disease during chronic hemodialysis: I. Association of bone disease with potentially etiologic factors. J Clin Invest 50: 592-598
6. Fournier AE et al. (1971) Etiology of hyperparathyroidism and bone disease during chronic hemodialysis: II. Factors affecting serum immunoreactive parathyroid hormone. J Clin Invest 50: 599-605
7. Touam M et al. (2005) High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism. Kidney Int 67: 2065
8. Block GA et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525
9. Ghazali A et al. (1999) Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 55: 2169-2177
10. Sadek T et al. (2003) Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 18: 582-588
11. Mucsi I et al. (2005) Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 64: 288-294
12. Fraser DR and Kodicek E (1970) Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 228: 764-766
13. Dusso AS (2003) Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl: S6-S9
14. Masuyama R et al. (2003) Dietary calcium and phosphorus ratio regulates bone mineralization and turnover in vitamin D receptor knockout mice by affecting intestinal calcium and phosphorus absorption. J Bone Miner Res 18: 1217-1226
15. Panda DK et al. (2001) Targeted ablation of the 25-hydroxyvitamin D1α-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 98: 7498-7503
16. Cozzolino M et al. (2001) p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60: 2109-2117
17. Silver J et al. (2001) Regulation of PTH secretion and synthesis and of parathyroid cell proliferation. In Spectrum of Renal Osteodystrophy, 25 (Eds Drücke T and Salusky I) Oxford: Oxford University Press
18. Ritter CS et al. (2002) Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res 17: 2206-2213
19. Schiavi SC and Kumar R (2004) The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 65: 1-14
20. Nakanishi S et al. (2005) Serum fibroblast growth factor-23 levels predict future refactory hyperparathyroidism in dialysis patients. Kidney Int 67: 1171-1178
21. Nagano N et al. (2006) Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 69: 531-537
22. Jolma P et al. (2003) Treatment of secondary hyperparathyroidism by high calcium diet is associated with enhanced resistance artery relaxation in experimental renal failure. Nephrol Dial Transplant 18: 2560-2569
23. Porsti I et al. (2004) High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure. Kidney Int 66: 2155-2166
24. 3-1α- hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87: 2967-2972
25. Ritter CS et al. (2005) 25 hydroxyvitamin D3 suppresses PTH synthesis and secretion by cultured bovine parathyroid cells: potential role for intracrine1.25(OH)2 D3. J Am Soc Nephrol 16: a750 (Poster SA PO 889)
26. Kos CH et al. (2003) The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 111: 1021-1028
27. Tu Q et al. (2003) Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest 111: 1029-1037
28. Colloton M et al. (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67: 467-476
29. Martin D et al. (2004) Regression of parathyroid hyperplasia by cinacalcet Hcl in a rodent model of chronic kidney disease. In Proceedings of the ERA XLI Congress; Lisbon, 318 (Poster MP262)
30. Llach F and Massry SG (1985) On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61: 601-606
31. Portale AA et al. (1987) Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus: implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 80: 1147-1154
32. Liu S and Chu H (1943) Studies of calcium phosphate metabolism with special reference to pathogenesis and effects of dihydrotachysterol and iron. Medicine 22: 103-161
33. 3 and 25(OH) vitamin D3. Kidney Int Suppl 24: S178-S179
34. Lafage MH et al. (1992) Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 42: 1217-1225
35. Hamdy NA et al. (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358-363
36. Ritz E et al. (1995) Low-dose calcitriol prevents the rise of 1-84 PTH without affecting serum calcium and phosphate in patients with moderate renal failure. Nephrol Dial Transplant 10: 2228-2234
37. Morinière P et al. (1985) Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 39: 309-315
38. Indridason OS and Quarles LD (2000) Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients: Durham Renal Osteodystrophy Study Group. Kidney Int 57: 282-292
39. Razzaque MS et al. (2006) Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20: 720-722
40. Haffner D et al. (2005) Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 23: 1067-1075
41. Phan O et al. (2004) Sevelamer prevents accelerated atherosclerosis in apolipoprotein E deficient (apoE-/-) mice with chronic renal failure (CRF) 5. J Am Soc Nephrol 15: a275 (Poster FPO962)
42. Cozzolino M et al. (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64: 1653-1661
43. Teng M et al. (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456
44. Tougaard L et al. (1976) Controlled trial of 1alpha- hydroxycholecalciferol in chronic renal failure. Lancet 1: 1044-1047
45. Christiansen C et al. (1978) Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 2: 700-703
46. Goldsmith DJ et al. (1997) Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 77: 37-43
47. Marangella M et al. (1993) Effects of oral and intravenous calcitriol on serum calcium oxalate saturation in dialysis patients. Clin Sci (Lond) 85: 309-314
48. Qunibi WY (2005) Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int Suppl: S43-S50
49. Chertow GM et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252
50. London GM et al. (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15: 1943-1951
51. Renaud H et al. (1988) Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate. Nephron 48: 28-32
52. Fournier A et al. (1997) The clinical significance of adynamic bone disease in uremia. In Advances in Nephrology Year-Book, vol 27, 131-166 (Ed Grünfeld JP). St Louis: Mosby
53. Mansour J et al. (2005) Vascular calcifications, oral calcium dose and mortality of hemodialysis patients: any causal relationship? Nephrol Dial Transplant 101: SP244
54. Braun J et al. (1996) Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394-401
55. Teng M et al. (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115-1125
56. LaClair RE et al. (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026-1033
57. Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80: 1678S-1688S
58. 3-1α- hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111: 1666-1671
59. Agarwal R et al. (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823-2828
60. Fournier A et al. (1982) Prevention and medical treatment of hyperparathyroidism secondary to renal failure in the adult. In Advances in Nephrology, vol 11, 241-268 (Ed Hamburger J) Chicago: YearBook Medical Publisher
61. Cannata-Andia JB and Gomez Alonso C (2002) Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. Nephrol Dial Transplant 17: 1875-1878
62. Delmez JA et al. (1992) Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 3: 96-102
63. Ben Hamida F et al. (1993) Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate-binder. Nephron 63: 258-262
64. Damment J et al. (2004) The bone kinetics of lanthanum in dialysis patient treated with lanthanum carbonate up to 4.5 years. J Am Soc Nephrol 15: a271 (Poster FPO 948)
65. Lacour B et al. (2005) Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67: 1062-1069
66. Takahashi Y et al. (2004) Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099-1104
67. Capuzzi DM et al. (1998) Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 82: 74U-81U
68. Rottembourg JB et al. (2005) Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 68: 2911-2912
69. Rutkowski B et al. (2003) N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? Kidney Int Suppl: S19-S21
70. Jagtap P and Szabo C (2005) Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421-440
71. Manns B et al. (2004) A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66: 1239-1247